SFS
FPRX

Sowell Financial Services’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Sowell Financial Services’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-405
Closed -$19K – 603
2016
Q4 		$19K Buy
+405
New +$21.3K 0.01% 431

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Sowell Financial Services's FPRX Position: Q1 2017 in Review

Sowell Financial Services sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2017, closing a stake of 405 shares — an estimated $19K sold.

Sowell Financial Services first reported a position in FPRX in Q4 2016 and held it in 1 quarter. The position peaked at $19K in Q4 2016. 157 funds tracked by Wall St. Rank hold FPRX as of Q1 2017.

  • Sowell Financial Services reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Sowell Financial Services sold 405 Five Prime Therapeutics, Inc. shares in Q1 2017, an estimated $19K.
  • Sowell Financial Services first reported a position in Five Prime Therapeutics, Inc. in Q4 2016 and held it in 1 quarter.
  • Sowell Financial Services's Five Prime Therapeutics, Inc. position peaked at $19K in Q4 2016.
  • 157 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2017.

Based on Sowell Financial Services's 13F filing for Q1 2017, filed 31 May 2017.